Skip Ribbon Commands
Skip to main content
releases

Releases

 

SER=Stock exchange release          PR=Press release

 

Select year:  

2014-09-29 SER Biotie's Financial Information in 2015
2014-09-19 SER Biotie: Selincro enters the market in France
2014-08-29 SER Biotie: Selincro enters the market in Germany
2014-08-28 SER Biotie: Formal transfer of global rights for tozadenant to Biotie concluded
2014-08-21 SER Change in the number of votes relating to Biotie Therapies Corp.'s shares
2014-08-21 SER Change in the number of votes relating to Biotie Therapies Corp.'s shares
2014-08-01 SER Correction to Biotie Therapies Corp. interim report for January - June 2014
2014-08-01 SER Correction to Stock Exchange Release: Change in the number of votes relating to Biotie Therapies Corp.'s shares published 30 July at 8.45 am
2014-07-30 SER Biotie interim report 1 January - 30 June 2014
2014-07-30 SER Biotie updates outlook on tozadenant and SYN120
2014-07-30 SER Change in the number of votes relating to Biotie Therapies Corp.'s shares
2014-07-30 SER Change in the number of votes relating to Biotie Therapies Corp.'s shares
2014-07-24 SER Clinical study with Biotie's BTT1023 in primary sclerosing cholangitis awarded external grant funding
2014-07-22 SER Biotie: Selincro enters the market in Spain
2014-07-11 SER Biotie decides not to exercise option to acquire Neurelis, Inc. but retains economic interest in future success of NRL-1
2014-07-10 SER Biotie: Selincro receives positive draft guidance from UK's NICE
2014-07-08 SER Biotie: Tozadenant Phase 2b Parkinson's disease study published in Lancet Neurology
2014-07-08 SER Biotie awarded USD 2 million grant from The Michael J. Fox Foundation for a clinical study with SYN120 in Parkinson's Disease Dementia
2014-06-03 SER Change in the number of votes relating to Biotie Therapies Corp.'s shares
2014-05-27 SER Biotie: nepicastat study in cocaine dependence completes enrollment ahead of schedule - top-line data expected around end 2014
2014-05-09 SER Biotie: Change in the number of votes
2014-05-09 SER Biotie interim report 1 January - 31 March 2014
2014-05-06 SER Change in the number of votes relating to Biotie Therapies Corp.'s shares
2014-04-03 SER Biotie: Change in the number of votes
2014-04-03 SER RESOLUTIONS OF THE ANNUAL GENERAL MEETING OF BIOTIE THERAPIES CORP. AND ORGANIZATION OF THE BOARD
2014-03-21 SER Biotie to regain global rights to tozadenant from UCB
2014-03-04 SER Biotie's Financial Statement Report and Corporate Governance Statement 2013 published
2014-02-28 SER INVITATION TO THE ANNUAL GENERAL MEETING OF BIOTIE THERAPIES CORP.
2014-02-28 SER Biotie Financial Statement Release 2013
2014-02-28 SER Biotie updates outlook: Intends to develop SYN120 internally and will not exercise its option to acquire Neurelis until further notice
2014-02-28 SER Biotie: Change in the number of votes
2014-01-28 SER Biotie: Change in the number of votes
2014-01-08 SER New Treasury Shares of Biotie Therapies Corp registered with the Trade Register
2014-01-03 SER The Board of Directors of Biotie Therapies Corp. has Approved Three Year Incentive Plans for Employees
2014-01-03 SER Issue of new treasury shares of Biotie Therapies Corp without consideration
2014-01-03 SER Change in the number of votes relating to Biotie Therapies Corp.'s shares